Clinical Trials Logo

HCV Infection clinical trials

View clinical trials related to HCV Infection.

Filter by:

NCT ID: NCT00850044 Completed - HCV Infection Clinical Trials

Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1

Start date: February 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the pharmacokinetic and safety profiles of an experimental HCV protease inhibitor with and without ritonavir in healthy volunteers.

NCT ID: NCT00768690 Completed - HCV Infection Clinical Trials

A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333

Start date: October 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine multiple dose safety, tolerability and pharmacokinetics of ABT-333 under nonfasting conditions in healthy adult subjects, and to determine the effect of single dose administration of ketoconazole on steady state ABT-333 pharmacokinetics

NCT ID: NCT00743795 Completed - HCV Infection Clinical Trials

Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

Start date: October 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the safety, tolerability and effectiveness of the experimental drug GS-9190 when administered for 24 or 48 weeks with peginterferon alfa 2a and ribavirin for the treatment of genotype-1 chronic hepatitis C infection.

NCT ID: NCT00726882 Completed - HCV Infection Clinical Trials

A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies

Start date: August 2008
Phase: Phase 2
Study type: Interventional

The purpose of this follow-up study is to evaluate the frequency and persistence of specific viral mutations in response to treatment with ABT-333 (dasabuvir).

NCT ID: NCT00725803 Completed - HCV Infection Clinical Trials

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV

Start date: April 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to examine the safety, tolerability, pharmacokinetics (studies how the body processes a drug), and initial activity of GS-9450 in preventing liver damage due to scarring, or fibrosis, caused by Hepatitis C Virus (HCV) infection.

NCT ID: NCT00696904 Completed - HCV Infection Clinical Trials

Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects

Start date: June 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, pharmacokinetics of ABT-333 in healthy volunteers and the antiviral activity in HCV infected subjects.

NCT ID: NCT00623649 Completed - HCV Infection Clinical Trials

Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection

Start date: November 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether a 3-day course of therapy with orally administered VCH-916 given at different dosages can effectively reduce the amount of circulating virus (i.e., viral load) in patients with early-stage chronic hepatitis C-infection. This study will also evaluate the safety and tolerability of treatment with VCH-916. Blood samples will also be taken to measure the levels of VCH-916 present in plasma at various time points during the treatment period.

NCT ID: NCT00221624 Completed - Clinical trials for Hepatitis C, Chronic

Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients

PEGARI
Start date: November 2001
Phase: Phase 3
Study type: Interventional

Response to a second-line anti-HCV treatment in non responder patients to a first-line dual therapy remains very poor. Preliminary studies of amantadine suggest that this drug could be potentially effective to treat hepatitis C.

NCT ID: NCT00170131 Completed - Clinical trials for Liver Transplantation

MMF Influence on HCV Viral Evolution After Liver Transplantation

Start date: September 2002
Phase: Phase 4
Study type: Observational

Samples from a large clinical trial comparing three immunosuppression regimens, two of which contained MMF, are used to identify the HCV viral quasispecies behaviour after liver transplantation